The Future of Psilocybin Therapy: What FDA Approval Could Mean for Clients
When you have spent years trying to feel better, news of a possible new treatment can bring both hope and questions. Could this help me? How soon might it be available? What would the experience involve?
Psilocybin treatment is moving through an important chapter of clinical research and regulatory review. As a psychotherapist offering ketamine-assisted psychotherapy (KAP) and psychedelic integration, I am following these developments with interest—and with respect for the careful work still ahead.
Where are we now?
Psilocybin is the psychedelic compound found in certain mushrooms. The research focuses on carefully measured products delivered with screening, supervision, and support.
One program attracting attention is COMP360, an investigational synthetic psilocybin product developed by Compass Pathways for treatment-resistant depression. The company has reported positive results from two Phase 3 trials. In September 2026, it also announced longer-term findings from an open-label extension, in which participants knew they were receiving active treatment. Those findings are encouraging, but open-label results have limitations and do not establish that everyone will benefit.[1,2]
As of this update, COMP360 remains investigational. Compass reports that its rolling FDA application submission and review are underway, with completion of the application expected in late 2026. The company anticipates a possible launch in the first half of 2027, subject to FDA approval and DEA rescheduling. This is a projected timeline, not a confirmed approval or availability date.[1,2]
What would FDA approval actually mean?
The FDA evaluates specific drug products for specific uses. A possible approval for a psilocybin product targeting treatment-resistant depression would not mean that every form of psilocybin—or every proposed use for anxiety, trauma, or personal growth—had been approved.
The FDA has issued guidance for psychedelic drug research and is considering questions about future therapeutic use.[3]
For clients, the details of any eventual approval would matter: who qualifies, what screening is required, where treatment can take place, and what monitoring and follow-up are needed.
What might this mean for someone seeking help?
The possibility of another treatment option can be meaningful, particularly for people whose depression has not improved enough with existing approaches. Still, a promising treatment is not a guaranteed solution or the right fit for every person.
Psilocybin can produce intense changes in perception and consciousness. Thoughtful research and medical assessment are essential to understanding its benefits and risks.[3] If a product becomes available, clients would need individualized guidance about eligibility, health history, medications, and alternatives.
Practical questions also remain: What will treatment cost? Will insurance cover it? Which providers and locations will offer it? These answers will help clients understand what access could look like in their own communities.
You do not need to put your current care on hold while waiting. Your therapist and medical provider can help you consider the support available now.
Where does psychotherapy fit?
In my work, preparation and integration provide room for questions, emotional support, and reflection. They help us explore what you are bringing into an experience and how you want to respond afterward.
A future approved psilocybin treatment may follow a different structure from KAP. The exact role and requirements of psychotherapy would depend on the approved treatment pathway. What remains central to my approach is making room for your questions, your experience, and the ongoing work of caring for yourself.
What this could mean for the care I offer clients
My ongoing training and professional connections with both the Integrative Psychiatry Institute (IPI) and Journey Clinical support my continued learning in this evolving field. Both organizations are involved in efforts to prepare providers for potential future COMP360 care through education or research collaboration.[4,5] I am following these developments with interest as I consider how my practice may grow.
As appropriate legal and clinical pathways become available, I am hopeful about the possibility of expanding the treatment options in my practice. Additional medicines could offer more ways to support each person's unique needs and create new possibilities for healing. My intention is to approach any future offering thoughtfully, with the necessary training, medical collaboration, and attention to safety, preparation, and integration.
At this time, I do not provide psilocybin dosing. My practice offers individual KAP and psychedelic integration therapy for adults. I provide psychotherapy, preparation, and integration support, while a separate medical provider handles medical evaluation and prescribing. I do not prescribe medication.
Hope, with room for honest questions
There is room to feel hopeful without having every answer yet. My commitment is to stay informed, communicate clearly, and help clients make thoughtful decisions about their care.
For adults in Irvine and throughout California, I offer preparation and integration psychotherapy through telehealth when appropriate, with KAP medicine sessions held in person in my Irvine office.
If you are curious about the KAP or integration services currently available, contact me to ask about scheduling an intake. We can begin with your questions, your history, and what you need today.
This article is educational and does not replace individualized medical advice. Research and regulatory timelines may change.